Related Experiment Video
Updated: Aug 30, 2026

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation
Published on: January 16, 2019
Releasing the true power of protease inhibitors
1Infectious Diseases Department, University Hospital, Nantes, France. francois.raffi@wanadoo.fr
Abstract:
Atazanavir is a potent, novel and highly selective inhibitor of the HIV-1 protease, with a low pill burden and once-daily dosing. Clinical studies have shown atazanavir to be the first protease inhibitor (PI) to have equivalent efficacy to efavirenz over a 48-week period of follow-up in PI-treatment-naïve patients. Loss of susceptibility to atazanavir in PI-naïve patients occurs infrequently and is not associated with cross-resistance to other PIs. In clinical trials, atazanavir has shown better gastrointestinal tolerability than other PIs. Also, unlike other PIs, atazanavir has been associated with decreases, or only minimal increases, in lipid parameters such as low-density lipoprotein cholesterol and triglycerides.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
The Proteasome Structure
The proteasome is an...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme Inhibition

